SS
ACRS icon

SBI Securities’s Aclaris Therapeutics ACRS Stock Holding History

SBI Securities’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251 Sell
67
-12
-15% -$40 ﹤0.01% 3132
2025
Q4 		$238 Sell
79
-160
-67% -$404 ﹤0.01% 3154
2025
Q3 		$454 Sell
239
-28
-10% -$49 ﹤0.01% 3009
2025
Q2 		$379 Buy
267
+200
+299% +$271 ﹤0.01% 3075
2025
Q1 		$103 Buy
67
+1
+2% +$2 ﹤0.01% 3430
2024
Q4 		$164 Buy
+66
New +$164 ﹤0.01% 3311

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SBI Securities's ACRS Position: Q1 2026 in Review

SBI Securities reduced its Aclaris Therapeutics (ACRS) stake by 15% in Q1 2026, selling an estimated $40 and leaving 67 shares worth $251. The position accounts for ﹤0.01% of the portfolio, ranked #3132.

SBI Securities first reported a position in ACRS in Q4 2024 and has held it in 6 quarters since. The position peaked at $454 in Q3 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • SBI Securities held 67 shares of Aclaris Therapeutics worth $251 as of Q1 2026.
  • SBI Securities sold 12 Aclaris Therapeutics shares in Q1 2026, an estimated $40.
  • Aclaris Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3132 holding.
  • SBI Securities first reported a position in Aclaris Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Aclaris Therapeutics position peaked at $454 in Q3 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.